These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10912535)
1. Modulation of endochondral bone formation: roles of growth hormone, 1,25-dihydroxyvitamin D and hyperparathyroidism. Sanchez CP Pediatr Nephrol; 2000 Jul; 14(7):646-9. PubMed ID: 10912535 [TBL] [Abstract][Full Text] [Related]
2. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. Sanchez CP; He YZ J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789 [TBL] [Abstract][Full Text] [Related]
3. Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism. Sanchez CP; He YZ Kidney Int; 2007 Sep; 72(5):582-91. PubMed ID: 17554252 [TBL] [Abstract][Full Text] [Related]
4. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Sanchez CP; Salusky IB; Kuizon BD; Abdella P; Jüppner H; Goodman WG Kidney Int; 1998 Dec; 54(6):1879-87. PubMed ID: 9853253 [TBL] [Abstract][Full Text] [Related]
5. Growth retardation in children with chronic renal failure. Kuizon BD; Salusky IB J Bone Miner Res; 1999 Oct; 14(10):1680-90. PubMed ID: 10491215 [TBL] [Abstract][Full Text] [Related]
6. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kuizon BD; Goodman WG; Jüppner H; Boechat I; Nelson P; Gales B; Salusky IB Kidney Int; 1998 Jan; 53(1):205-11. PubMed ID: 9453020 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure. Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842 [TBL] [Abstract][Full Text] [Related]
8. Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism. Salusky IB; Goodman WG; Kuizon BD Pediatr Nephrol; 2000 Jul; 14(7):641-5. PubMed ID: 10912534 [TBL] [Abstract][Full Text] [Related]
9. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712 [TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
11. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D analogues for the management of secondary hyperparathyroidism. Martin KJ; González EA Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385 [TBL] [Abstract][Full Text] [Related]
13. PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy. Schindler S; Mannstadt M; Urena P; Segre GV; Stein G Clin Nephrol; 2004 Apr; 61(4):253-60. PubMed ID: 15125031 [TBL] [Abstract][Full Text] [Related]
14. Intermittent calcitriol therapy and growth in children with chronic renal failure. Kuizon BD; Salusky IB Miner Electrolyte Metab; 1998; 24(4):290-5. PubMed ID: 9554570 [TBL] [Abstract][Full Text] [Related]
15. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547 [TBL] [Abstract][Full Text] [Related]
16. Growth hormone therapy in calcium-loaded rats with renal failure. Sanchez CP; He YZ Endocrinology; 2004 Jul; 145(7):3375-85. PubMed ID: 15044375 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195 [TBL] [Abstract][Full Text] [Related]
18. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208 [TBL] [Abstract][Full Text] [Related]
19. Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia. Jara A; Chacón C; Valdivieso A; Aris L; Jalil R; Felsenfeld AJ Nephrol Dial Transplant; 2001 May; 16(5):1009-16. PubMed ID: 11328908 [TBL] [Abstract][Full Text] [Related]
20. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Ureña P; Ferreira A; Morieux C; Drüeke T; de Vernejoul MC Nephrol Dial Transplant; 1996 Oct; 11(10):2008-16. PubMed ID: 8918715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]